Open Journal Systems

Personalized hormonal treatment for prostate cancer: An opportunity for improvement

Omar Abdel-Rahman ()


Not applicable.


Prostate cancer; Abiraterone acetate; Hormonal treatment

Full Text:



Abdel-Rahman O. Combined chemohormonal strategy in hormone-sensitive prostate cancer: A pooled analysis of randomized studies. Clin Genitourin Cancer 2015. doi: 10.1016/j.clgc.2015.12.004.

Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (suppl 5): v69-v77. doi: 10.1093/annonc/mdv222.

Crawford ED, Stone NN, Evan YY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP, Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group. Challenges and recommendations for early identifi-cation of metastatic disease in prostate cancer. Urology 2014; 83(3): 664-9. doi: j.urology.2013.10.026.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abi-raterone in prostate cancer. N Engl J Med 2014; 371(11): 1028-38. doi: 10.1056/NEJMoa1315815.

Mandelkow R, Brunnert D, Weiss M, Burchardt M, Stope MB. Lysophosphatidic acid receptor isoforms expression in prostate cancer cells is differentially regulated by the CYP17A1 inhibitor abiraterone and depends on the androgen receptor. Adv Mod Oncol Res 2016. doi: 10.18282/amor.v2.i1.83.



  • There are currently no refbacks.

Copyright (c) 2018 Omar Abdel-Rahman

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.